Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Wim L.J. van Putten"'
Autor:
Gilles Salles, Ama Z. S. Rohatiner, Jelle W. Kylstra, Hervé Tilly, Barbara Botto, Pierre Soubeyran, Achiel Van Hoof, Angelika Bischof-Delaloye, Franck Morschhauser, Anton Hagenbeek, Wim L.J. van Putten, John Radford
Publikováno v:
Journal of clinical oncology, 31(16), 1977-1983. American Society of Clinical Oncology
Purpose Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 (90Y) –ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. Patients and Methods P
Autor:
Luca Incrocci, Wim L.J. van Putten, Gerard J. van der Wielen, Abrahim Al-Mamgani, Peter C. Levendag
Publikováno v:
International Journal of Radiation Oncology Biology Physics, 79(4), 1004-1012. Elsevier Inc.
Purpose: To assess the impact of dose escalation of radiotherapy on quality of life (QoL) in prostate cancer patients. Patients and Methods: Three hundred prostate cancer patients participating in the Dutch randomized trial (CKTO 69-10) comparing 68
Autor:
Daphne de Jong, Anton Hagenbeek, Mars B. van 't Veer, Hanneke C. Kluin-Nelemans, Marinus H. J. van Oers, Wim L.J. van Putten, J. M. Zijlstra, M.A. MacKenzie
Publikováno v:
van 't Veer, M B, de Jong, D, MacKenzie, M, Kluin-Nelemans, H C, van Oers, M H J, Zijlstra-Baalbergen, J M, Hagenbeek, A & van Putten, W L J 2009, ' High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients ', British Journal of Haematology, vol. 144, no. 4, pp. 524-530 . https://doi.org/10.1111/j.1365-2141.2008.07498.x
British Journal of Haematology, 144, 524-30
British Journal of Haematology, 144, 4, pp. 524-30
British Journal of Haematology, 144(4), 524-530. Wiley-Blackwell Publishing Ltd
British journal of haematology, 144(4), 524-530. Wiley-Blackwell
British Journal of Haematology, 144(4), 524-530. Wiley-Blackwell
British Journal of Haematology, 144(4), 524-530. Wiley
British Journal of Haematology, 144, 524-30
British Journal of Haematology, 144, 4, pp. 524-30
British Journal of Haematology, 144(4), 524-530. Wiley-Blackwell Publishing Ltd
British journal of haematology, 144(4), 524-530. Wiley-Blackwell
British Journal of Haematology, 144(4), 524-530. Wiley-Blackwell
British Journal of Haematology, 144(4), 524-530. Wiley
Contains fulltext : 80496.pdf (Publisher’s version ) (Closed access) Mantle cell lymphoma (MCL) has a dismal outcome when treated with conventional chemotherapy. This single arm phase 2 study evaluated intensive consolidation treatment of patients
Autor:
Peter J. M. Valk, Ruud Delwel, Bas J. Wouters, Bob Löwenberg, Claudia A.J. Erpelinck-Verschueren, Wim L.J. van Putten
Publikováno v:
Blood, 113(13), 3088-3091. American Society of Hematology
Mutations in CCAAT/enhancer binding protein α (CEBPA) are seen in 5% to 14% of acute myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most AMLs with CEBPA mutations simultaneously carry 2 mutations (CEBPAdouble-mut)
Autor:
Anne Hagemeijer, Clemens Mellink, Georgine E. de Greef, Shama L. van Zelderen-Bhola, Wim L.J. van Putten, Martine Jotterand, Aggie W. M. Nieuwint, Dimitri Breems, H. Berna Beverloo, Klasien B. J. Gerssen-Schoorl, Bob Löwenberg
Publikováno v:
Journal of Clinical Oncology, 26(29), 4791-4797. American Society of Clinical Oncology
Journal of Clinical Oncology, 26(29), 4791-4797. AMER SOC CLINICAL ONCOLOGY
Breems, D A, Van Putten, W L J, De Greef, G E, Van Zelderen-Bhola, S L, Gerssen-Schoorl, K B J, Mellink, C H M, Nieuwint, A, Jotterand, M, Hagemeijer, A, Beverloo, H B & Löwenberg, B 2008, ' Monosomal karyotype in acute myeloid leukemia : A better indicator of poor prognosis than a complex karyotype ', Journal of Clinical Oncology, vol. 26, no. 29, pp. 4791-4797 . https://doi.org/10.1200/JCO.2008.16.0259
Journal of clinical oncology, 26(29), 4791-4797. American Society of Clinical Oncology
Journal of Clinical Oncology, 26(29), 4791-4797. AMER SOC CLINICAL ONCOLOGY
Breems, D A, Van Putten, W L J, De Greef, G E, Van Zelderen-Bhola, S L, Gerssen-Schoorl, K B J, Mellink, C H M, Nieuwint, A, Jotterand, M, Hagemeijer, A, Beverloo, H B & Löwenberg, B 2008, ' Monosomal karyotype in acute myeloid leukemia : A better indicator of poor prognosis than a complex karyotype ', Journal of Clinical Oncology, vol. 26, no. 29, pp. 4791-4797 . https://doi.org/10.1200/JCO.2008.16.0259
Journal of clinical oncology, 26(29), 4791-4797. American Society of Clinical Oncology
Purpose To investigate the prognostic value of various cytogenetic components of a complex karyotype in acute myeloid leukemia (AML). Patients and Methods Cytogenetics and overall survival (OS) were analyzed in 1,975 AML patients age 15 to 60 years.
Autor:
Luca Incrocci, Gerard J. van der Wielen, Gert R. Dohle, Wim L.J. van Putten, Mischa S. Hoogeman
Publikováno v:
International Journal of Radiation Oncology Biology Physics, 71(3), 795-800. Elsevier Inc.
Purpose: To analyze the correlation between dose-volume parameters of the corpora cavernosa and erectile dysfunction (ED) after external beam radiotherapy (EBRT) for prostate cancer. Methods and Materials: Between June 1997 and February 2003, a rando
Autor:
Wim L.J. van Putten, Gustaaf W. van Imhoff, Marinus H. J. van Oers, Josée M. Zijlstra, Mars B. van 't Veer, Leo F. Verdonck, Pierre W. Wijermans, Peter C. Huijgens, Edo Vellenga, Pieternella J. Lugtenburg, Willem E. Fibbe
Publikováno v:
Blood, 111(2), 537-543. American Society of Hematology
Vellenga, E, van Putten, W L, van 't Veer, M B, Zijlstra-Baalbergen, J M, Fibbe, W E, van Oers, M H, Verdonck, L F, Wijermans, P W, van Imhoff, G W, Lugtenburg, P J & Huijgens, P C 2008, ' Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial ', Blood, vol. 111, no. 2, pp. 537-543 . https://doi.org/10.1182/blood-2007-08-108415
Vellenga, E, van Putten, W L, van 't Veer, M B, Zijlstra-Baalbergen, J M, Fibbe, W E, van Oers, M H, Verdonck, L F, Wijermans, P W, van Imhoff, G W, Lugtenburg, P J & Huijgens, P C 2008, ' Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial ', Blood, vol. 111, no. 2, pp. 537-543 . https://doi.org/10.1182/blood-2007-08-108415
We evaluated the role of rituximab during remission induction chemotherapy in relapsed aggressive CD20+ non-Hodgkin lymphoma. Of 239 patients, 225 were evaluable for analysis. Randomized to DHAP (cisplatin-cytarabine-dexamethasone)-VIM (etoposide-ifo
Publikováno v:
International Journal of Radiation Oncology Biology Physics, 68(2), 479-484. Elsevier Inc.
Purpose: The purpose of this study is to provide information about sexual function (SF) after three-dimensional conformal radiotherapy (3D-CRT) for prostate cancer while taking important factors into account that influence SF. Methods and Materials:
Autor:
Luca Incrocci, Peter C.M. Koper, Johannes M.G. Bonfrer, Joos V. Lebesque, Stephanie T.H. Peeters, Wim L.J. van Putten, Michel F.H. Dielwart, Annerie Slot, Wilma D. Heemsbergen
Publikováno v:
Journal of Clinical Oncology, 24(13), 1990-1996. American Society of Clinical Oncology
Purpose To determine whether a dose of 78 Gy improves outcome compared with a conventional dose of 68 Gy for prostate cancer patients treated with three-dimensional conformal radiotherapy. Patients and Methods Between June 1997 and February 2003, sta
Autor:
Peter C.M. Koper, Joos V. Lebesque, Annerie Slot, Wim L.J. van Putten, Stephanie T.H. Peeters, Wilma D. Heemsbergen, Michel F.H. Dielwart
Publikováno v:
International Journal of Radiation Oncology Biology Physics, 64(4), 1151-1161. Elsevier Inc.
Purpose: To identify dosimetric parameters derived from anorectal, rectal, and anal wall dose distributions that correlate with different late gastrointestinal (GI) complications after three-dimensional conformal radiotherapy for prostate cancer. Met